Japanese pharmaceutical companies’ Korean offshoots recorded low growth in 2021, according to their audit reports.The audit reports showed that the combined sales of the nine Japanese drugmakers’ Korean offshoots stood at 1.44 trillion won ($1 billion) last year, marking an increase of a mere 1.4 pe
GC Wellbeing said on Friday that it signed a technology transfer contract with Japan's Healthy Navi for its functional raw material Green Cera-F, a honey suckle bud extract.Green Cera-F is a raw material that has been recognized by the Ministry of Food and Drug Safety for its functionality that can
The government is wielding excessive power to lower drug prices without recognizing the values of innovative medicines, an expert said.Kim Sung-ju, an expert advisor for Lee & Ko’s Healthcare Practice Group, published an article in the Korea Pharmaceutical and Bio-Pharma Manufacturers Association’s
Bayer Korea said it would continue marketing Nebido, its long-acting injectable for males with testosterone deficiency, in the country, although its headquarters handed over the drug’s global rights to Grünenthal, a German pharmaceutical company.Grünenthal has picked up the global rights for the dru
Korea saw a trade surplus in vaccines for humans for the first time in the first half of this year, raising expectations for further growth of the vaccine industry.According to a report on exports and imports of human vaccines and diagnostic agents, published by the Korea Biotechnology Industry Orga
GenScript ProBio signed a memorandum of understanding with DAAN Bio Therapeutics to cooperate to discover and develop innovative drugs on Thursday.Through this MOU, GenScript ProBio and DAAN agreed to strengthen their cooperation, specifically in the cell and gene therapy (CGT) and biologics field.T
The U.S. FDA put off a decision on whether to approve tislelizumab, anti-PD-1 immunotherapy developed by BeiGene and Novartis, due to Covid-19-related travel restrictions.BeiGene, the Chinese pharmaceutical firm, said on Thursday that the FDA deferred a decision on approval for tislelizumab as a sec
The Research Investment for Global Health Technology Fund (RIGHT Fund) committed an additional 4 billion won ($3 million) to support four newly selected research projects concerning infectious diseases in the first half of 2022.The four recipients of the additional grants are CHA Vaccine Institute,
GC Biopharma said Thursday it has received an investigational new drug (IND) approval from the Ministry of Food and Drug Safety for the researcher-led administration of Neulapeg on the same day after anticancer chemotherapy.The company said it is the first such clinical trial to be held in Korea.Neu
Study results to be presented at the WCLC in August will influence the direction of Yuhan Corp's Leclaza (Ingredient: lazertinib), the nation's 31st novel drug for NSCLC, and the corporate's value, a local analyst said."Yuhan will present three abstracts concerning its non-small cell lung cancer (NS
The clinical trial result of HLB’s targeted anticancer medicine rivoceranib will be presented at the 2022 International Association for the Study of Lung Cancer (IASLC 2022), the company said Thursday.IASLC, the world’s largest symposium for lung cancer and other thoracic malignancy, will be held in
Fears of Covid-19 resurgence are spreading, but SK Bioscience has yet to apply for a lot release of SKYCovione, the first homegrown Covid-19 vaccine.On Wednesday, SK Bioscience confirmed SKYCovicone’s immune response to the Omicron variant BA.1 in extended phase 1 and 2 trials.The company gave two d
SK Biopharmaceuticals said it signed a $62 million licensing agreement to commercialize cenobamate (brand name: Xcopri), an anti-epileptic treatment, in Latin America.In a public filing on Thursday, the company said it licensed out cenobamate to Eurofarma Laboratorios SA for the commercialization of
MSD’s anti-PD-1 therapy Keytuda (pembrolizumab) won expanded indication to be used as neoadjuvant therapy in combination with chemotherapy before surgery in patients with triple-negative breast cancer (TNBC) and then continued as a single agent after surgery.This indication allows Keytruda to treat
GemVax & Kael, an immunotherapy drug developer, said on Wednesday that the company had secured safety in the non-clinical toxicity trials of GV1001, the company’s 16-amino-acid peptide immunotherapy drug for pancreatic cancer.New substances generally require various strict conditions to be met to be
Bridge Biotherapeutics will present the phase 1 clinical trial’s result of BBT-176, the fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) drug, at the World Conference on Lung Cancer (WCLC) in Vienna next month.The conference organizers made public the abstract
Biomarker-based new drug developer MedPacto has applied to the U.S. Food and Drug Administration for the investigational new drug (IND) clinical trial of Vactosertib as a solo therapy for recurrent and intractable osteosarcoma patients.This upcoming clinical trial, a phase 1/2 trial of Vactosertib a
Neoimmuntech said Wednesday that the U.S. Food and Drug Administration has granted an orphan drug designation (ODD) for NT-I7, its immunotherapy candidate that treats glioblastoma multiforme (GBM), a type of brain cancer.It was the fourth ODD designation for NT-I7. It also received ODD designations
SK Bioscience’s SKYCovione, Korea's first locally developed Covid-19 vaccine, has shown cross-neutralizing activity against Omicron variant BA.1 as a booster shot administered after the primary vaccination, the company said Wednesday."Amid the rising possibility of the resurgence of Covid-19, we hav
Boehringer Ingelheim and Eli Lilly aim to dominate the chronic heart failure market with Jardiance, a Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor drug, armed with an expanded indication in treating heart failure with preserved ejection fraction (HFpEF).HFpEF is a clinical syndrome in which pa